报价延迟最少15分钟:2026/11/04 14:31 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.96/-1.25
|
|
企业价值
9.36M
|
| 资产负债 |
|
每股账面净值
3.75
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
13.19M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science. |
